Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Source: Eur Respir J 2004; 23: 76-81 Year: 2004
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Antigen-induced airway hyperresponsiveness and eosinophilia in mice is inhibited by the endothelin receptor antagonist SB217242 Source: Eur Respir J 2001; 18: Suppl. 33, 349s Year: 2001
CS-003, a novel triple neurokinin receptor antagonist, inhibits symptoms of respiratory diseases models in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
Inhibition of cough reflex by D2 receptor agonism with Viozan™ (AR-C68397AA) Source: Eur Respir J 2001; 18: Suppl. 33, 32s Year: 2001
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4 -induced contractions of isolated human bronchi Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
A new ultra-potent vanilloid receptor 1 (VR1) antagonist abates capsaicin and citric acid induced cough Source: Eur Respir J 2002; 20: Suppl. 38, 190s Year: 2002
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
The cannabinoid receptor agonist, WIN 55,212-2, inhibits antigen-induced plasma extravasation in guinea pig airways Source: Annual Congress 2010 - Models of airways disease Year: 2010
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004